← back to search

James D. Douketis

McMaster University · CA
Area of research
Cardiology and Cardiovascular Medicine · Internal Medicine
Research interest
Research interests include Venous Thromboembolism Diagnosis and Management, Atrial Fibrillation Management and Outcomes, Antiplatelet Therapy and Cardiovascular Diseases, and Cardiac, Anesthesia and Surgical Outcomes.
h-index
71
citations
23,025
works
352
NIH funding
primary concept
Medicine
email

Recent publications

Surgical and procedural bleed risk stratification for anticoagulated patients undergoing planned surgery: guidance from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis
Journal of Thrombosis and Haemostasis 2026cited by 1position: contributordoi
Perioperative management of antithrombotic therapy in patients with thrombotic antiphospholipid syndrome.
2026cited by 0position: contributordoi
Perioperative management of direct oral anticoagulants in patients having a high-bleed-risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE)-2 pilot randomized trial
Journal of Thrombosis and Haemostasis 2025cited by 7position: contributordoi
Perioperative use of factor concentrates and blood products—a survey of clinical practices in the United States: communication from the ISTH Subcommittee on Perioperative and Critical Care
Journal of Thrombosis and Haemostasis 2025cited by 4position: middledoi
Perioperative use of factor concentrates and blood products-a survey of clinical practices in the United States: communication from the ISTH Subcommittee on Perioperative and Critical Care.
2025cited by 1position: contributordoi
Guidelines and guidance: what is the path forward for the ISTH?
2025cited by 1position: contributordoi
Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH: reply.
2025cited by 1position: contributordoi
“Perioperative management of direct oral anticoagulants in patients having a high-bleed–risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation 2 pilot randomized trial”: reply
Journal of Thrombosis and Haemostasis 2025cited by 0position: contributordoi
Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.
2024cited by 27position: contributordoi
Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper
Thrombosis and Haemostasis 2024cited by 22position: middledoi
Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.
2024cited by 16position: contributordoi
Anticoagulation Stewardship to Bridge the Implementation Gap in Perioperative Anticoagulation Management.
2024cited by 2position: contributordoi
Perioperative management and outcomes in patients receiving low-dose rivaroxaban and/or aspirin: a subanalysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial.
2024cited by 2position: contributordoi
Perioperative management of apixaban in patients with advanced CKD undergoing a planned invasive procedure.
2024cited by 1position: contributordoi
Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.
2024cited by 0position: contributordoi
Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis
Journal of Thrombosis and Haemostasis 2023cited by 31position: middledoi
Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis.
2023cited by 24position: contributordoi
Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registry
Journal of Thrombosis and Haemostasis 2023cited by 10position: lastdoi
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
The Lancet Oncology 2022cited by 427position: middledoi
Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH.
2022cited by 27position: contributordoi
Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort.
2022cited by 15position: contributordoi
Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure.
2022cited by 13position: contributordoi
Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and meta-analysis.
2022cited by 11position: contributordoi
Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH.
2022cited by 7position: contributordoi
Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 2021cited by 159position: middledoi
Management of antithrombotic therapy after gastrointestinal bleeding: A mixed methods study of health-care providers.
2021cited by 12position: contributordoi
A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant.
2021cited by 7position: contributordoi
Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19
Journal of Thrombosis and Haemostasis 2020cited by 668position: lastdoi
Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.
2020cited by 478position: contributordoi
Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure
Blood Advances 2020cited by 66position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

· 20 papers (2020–2026)Jean M. Connors · Dana-Farber Cancer Institute10 papers (2020–2026)Jerrold H. Levy · Duke University Hospital10 papers (2013–2026)Alex C. Spyropoulos · Northwell Health8 papers (2012–2025)Sam Schulman · McMaster University7 papers (2015–2023)Joseph R. Shaw · University of Ottawa7 papers (2022–2026)Alex C. Spyropoulos · Icahn School of Medicine at Mount Sinai7 papers (2020–2026) · 6 papers (2023–2026)Walter Ageno · Aziende Socio Sanitarie Territoriale dei Sette Laghi4 papers (2013–2020)Deborah M. Siegal · Population Health Research Institute4 papers (2021–2026)Kenichi A. Tanaka · Oklahoma City University4 papers (2023–2025)Alfonso Tafur · Endeavor Charter School4 papers (2017–2023) · 3 papers (2022–2022)Charles Marc Samama · Université Claude Bernard Lyon 13 papers (2013–2020)Beverley J. Hunt · Guy's and St Thomas' NHS Foundation Trust3 papers (2020–2022)Peter Verhamme · Hospital Universitario La Paz3 papers (2015–2019)Jean M. Connors · Harvard University3 papers (2020–2025)Corinne Frère · Inserm2 papers (2023–2023)Stuart J. Connolly · Thrombolysis in Myocardial Infarction Study Group2 papers (2012–2017)Frederick A. Spencer · McMaster University2 papers (2012–2015)